Our above findings revealed a close association between Tregs and tumor cells concerning the prognosis of NSCLC patients and current research unveiled the interaction of PD-1/PD-L1 influencing the proliferation and function of FOXP3+ Treg cells [22–25], which could offer novel insights to enhance the efficacy of anti-PD-1/PD-L1 antibody treatments. This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.